Publicaciones en las que colabora con O. Pfaar (17)

2021

  1. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 3, pp. 1020-1030.e10

  2. Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 735-750

  3. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 1041-1052

  4. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 629-647

2020

  1. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

    Clinical and Translational Allergy

  2. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 7, pp. 1672-1688

  3. The role of mobile health technologies in allergy care: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 2, pp. 259-272

2019

  1. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

    Journal of Allergy and Clinical Immunology, Vol. 143, Núm. 3, pp. 864-879

  2. Comparison of International Systemic Adverse Reactions Due to Allergen Immunotherapy

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1298-1305.e3

  3. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

    Clinical and Translational Allergy, Vol. 9, Núm. 1

2018

  1. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 4, pp. 827-836

  2. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

    Clinical and Translational Allergy, Vol. 8, Núm. 1

2017

  1. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, Núm. 3, pp. 462-472

  2. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment

    Pediatric Allergy and Immunology, Vol. 28, Núm. 1, pp. 60-70

2016

  1. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

    Clinical and Translational Allergy, Vol. 6, Núm. 1

2014

  1. An EAACI "european Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": The methodology

    Clinical and Translational Allergy, Vol. 4, Núm. 1

2012

  1. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

    Clinical and Translational Allergy, Vol. 2, Núm. 1